Статья
Артериальная гипертензия и снижение минеральной плотности костей: неожиданные патогенетические механизмы
Артериальная гипертензия (АГ) и остеопороз относятся к основным возраст-ассоциированным состояниям, каждое из которых является причиной значительной заболеваемости и смертности. На сегодняшний день накоплены данные о связи между АГ, маркерами формирования костного матрикса и резорбции костной ткани. В настоящей обзорной статье обсуждается взаимосвязь между АГ и снижением минеральной плотности костной ткани, а также ранее неизвестные патогенетические механизмы, лежащие в ее основе.
1. Белая Ж. Е., Белова К. Ю., Бирюкова Е. В. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4-47. doi:10.14341/osteo12930.
2. Михайлов Е. Е., Беневоленская Л.И. Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний; 2003.
3. Лесняк О. М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Naturaprint: International Osteoporosis Foundation (CH); 2011;14(2):3-6. doi:10.14341/osteo201123-6.
4. Varacallo MA, Fox EJ, Paul EM, et al. Patients' response toward an automated orthopedic osteoporosis intervention program. Geriatr Orthop Surg Rehabil. 2013;4(3):89-98. doi:10.1177/2151458513502039.
5. Aldukhayel A. Prevalence and patterns of bone mineral density disorders among women in Buraidah, KSA. J Taibah Univ Med Sci. 2022;18(2):348-55. doi:10.1016/j.jtumed.2022.09.014.
6. Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018. NCHS Data Brief. 2021;(405):1-8.
7. Shatrugna V, Kulkarni B, Kumar PA, et al. Bone status of Indian women from a low-income group and its relationship to the nutritional status. Osteoporos Int. 2005;16(12):1827-35. doi:10.1007/s00198-005-1933-1.
8. Panahi N, Saeedi Moghaddam S, et al. Trend in global burden attributable to low bone mineral density in different WHO regions: 2000 and beyond, results from the Global Burden of Disease (GBD) study 2019. Endocr Connect. 2023;12(10):e230160. doi:10.1530/EC-23-0160.
9. Хозяинова Н.Ю., Царева В.М., Курбасова Ю.В. и др. Снижение минеральной плотности костной ткани — маркер сердечно-сосудистого ремоделирования. Тихоокеанский медицинский журнал. 2011;(4):58-61.
10. McCloskey E, Rathi J, Heijmans S, et al. Prevalence of FRAX risk factors and the osteoporosis treatment gap among women >70 years of age in routine primary care across 8 countries in Europe. Arch Osteoporos. 2022;17(1):20. doi:10.1007/s11657-021-01048-8.
11. Asaba Y, Ito M, Fumoto T, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009;24(2):241-50. doi:10.1359/jbmr.081006.
12. Yang S, Nguyen ND, Center JR, et al. Association between hypertension and fragility fracture: a longitudinal study. Osteoporos Int. 2014;25(1):97-103. doi:10.1007/s00198-013-2457-8.
13. Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354(9183):971-5.
14. Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001; 14(7 Pt 1):704-7. doi:10.1016/s0895-7061(01)01303-6.
15. Al-Hariri M, Aldhafery B. Association of Hypertension and Lipid Profile with Osteoporosis. Scientifica (Cairo). 2020; 2020: 7075815. doi:10.1155/2020/7075815.
16. Mussolino ME, Gillum RF. Bone mineral density and hypertension prevalence in postmenopausal women: results from the Third National Health and Nutrition Examination Survey. Ann Epidemiol. 2006;16:395-9. doi:10.1016/j.annepidem.2005.06.051.
17. Javed F, Khan SA, Ayers EW, et al. Association of hypertension and bone mineral density in an elderly African American female population. J Natl Med Assoc. 2012;104(3-4):172-8. doi:10.1016/s0027-9684(15)30140-1.
18. Woo J, Kwok T, Leung J, et al. Dietary intake, blood pressure and osteoporosis. J Hum Hypertens. 2009;23(7):451-5. doi:10.1038/jhh.2008.156.
19. Hanley DA, Brown JP, Tenenhouse A, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: crosssectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res. 2003;18:784-90. doi:10.1359/jbmr.2003.18.4.784.
20. He B, Yin L, Zhang M, et al. Causal Effect of Blood Pressure on Bone Mineral Density and Fracture: A Mendelian Randomization Study. Front Endocrinol (Lausanne). 2021;12:716681. doi:10.3389/fendo.2021.716681.
21. Yazici S, Yazici M, Korkmaz U, et al. Relationship between blood pressure levels and bone mineral density in postmenopausal Turkish women. Arch Med Sci. 2011;7(2):264-70. doi:10.5114/aoms.2011.22077.
22. Lidfeldt J, Holmdahl L, Samsioe G, et al. The influence of hormonal status and features of the metabolic syndrome on bone density: a population-based study of Swedish women aged 50 to 59 years. The women's health in the Lund area study. Metabolism. 2002;51(2):267-70. doi:10.1053/meta.2002.300001.
23. Mani K, Mani A. The significance of plasma collagen degradation products as biomarkers for advanced hypertensive heart disease. J Clin Hypertens (Greenwich). 2021;23(5):1017-9. doi:10.1111/jch.14205.
24. Querejeta R, Lopez B, Gonzalez A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2OO4;110(10):1263-8.
25. Hassager C, Jensen L, Johansen J, et al. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. Metabolism. 1991;40:205-8. doi:10.1016/0026-0495(91)90176-W.
26. Eriksen EF, Charles P, Melsen F, et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993;8:127-32. doi:10.1002/jbmr.5650080202.
27. Park SY, Ahn SH, Yoo JI, et al. Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. J Bone Metab. 2019;26(4):213-24. doi:10.11005/jbm.2019.26.4.213.
28. Feldbrin Z, Shargorodsky M. Bone remodelling markers in hypertensive patients with and without diabetes mellitus: link between bone and glucose metabolism. Diabetes Metab Res Rev. 2015; 31(7):752-7. doi:10.1002/dmrr.2668.
29. Fink HA, Litwack-Harrison S, Taylor BC, et al. Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the osteoporotic fractures in men (MrOS) study. Osteoporos Int. 2016;27:331-8.
30. Shimizu Y, Nakazato M, Sekita T, et al. Association between alkaline phosphatase and hypertension in a rural Japanese population: The Nagasaki Islands study. J Physiol Anthropol. 2013;32(1):10. doi:10.1186/1880-6805-32-10.
31. Webber M, Krishnan A, Thomas NG, et al. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 20052006. Clin Chem Lab Med. 2010;48(2):167-73. doi:10.1515/CCLM.2010.052.
32. Schutte R, Huisman HW, Malan L, et al. Alkaline phosphatase and arterial structure and function in hypertensive African men: the SABPA study. Int J Cardiol. 2013;167(5):1995-2001. doi:10.1016/j.ijcard.2012.05.035.
33. Lee JH, Lee JW, Lee YJ. The Relationship between Serum Alkaline Phosphatase and Arterial Stiffness in Korean Adults. J Atheroscler Thromb. 2019;26(12):1084-91. doi:10.5551/jat.48942.
34. Zhang Y, Li H, Xie D, et al. Positive Association Between Serum Alkaline Phosphatase and First Stroke in Hypertensive Adults. Front Cardiovasc Med. 2021;8:749196. doi:10.3389/fcvm.2021.749196.
35. Kunutsor SK, Apekey TA, Khan H.Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236(1):7-17. doi:10.1016/j.atherosclerosis.2014.06.006.
36. Hu Z, Yang K, Hu Z, et al. Determining the association between hypertension and bone metabolism markers in osteoporotic patients. Medicine (Baltimore). 2021;100(24):e26276. doi:10.1097/MD.0000000000026276.
37. Bezerra dos Santos Magalhaes K, Magalhaes MM, Diniz ET, et al. Metabolic syndrome and central fat distribution are related to lower serum osteocalcin concentrations. Ann Nutr Metab. 2013;62(3):183-8. doi:10.1159/000342561.
38. Choi BH, Joo NS, Kim MJ, et al. Coronary artery calcification is associated with high serum concentration of undercarboxylated osteocalcin in asymptomatic Korean men. Clin Endocrinol (Oxf). 2015;83(3):320-6. doi:10.1111/cen.12792.
39. Chen YN, Wei P, Yu Bs J. Higher concentration of serum C-terminal cross-linking telopeptide of type I collagen is positively related with inflammatory factors in postmenopausal women with H-type hypertension and osteoporosis. Orthop Surg. 2019; 11(6):1135-41. doi:10.1111/os.12567.
40. Костина Д. А., Успенский В. Е., Семенова Д. С. и др. Молекулярные механизмы сосудистой кальцификации. Трансляционная медицина. 2020;7(1):6-21. doi:10.18705/2311-4495-2020-7-1-6-21.
41. Caesar C, Lyle AN, Joseph G, et al. Cyclic Strain and Hypertension Increase Osteopontin Expression in the Aorta. Cell Mol Bioeng. 2017;10(2):144-52. doi:10.1007/s12195-016-0475-2.
42. Lorenzen JM, Neunhoffer H, David S, et al. Angiotensin II receptor blocker and statins lower elevated levels of osteo-pontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis. 2010;209:184-8. doi:10.1016/j.atherosclerosis.2009.09.009.
43. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprote-gerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49(6):1392-8. doi:10.1161/HYPERTENSIONAHA.107.087742.
44. Kuipers AL, Kammerer CM, Pratt JH, et al. Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families. Hypertension. 2016;67(5):977-82. doi:10.1161/HYPERTENSIONAHA.115.06837.
45. Cakmak T, Kadife i, Ayhan E, et al. The relationship between osteoporosis and non-dipper hypertension in postmenopausal women. J Health Sci Med. 2023;6(5):898-904.
46. Нуруллина Г. М., Ахмадуллина Г. И., Маслова И.С. Функциональный гипопаратиреоз: причины, патогенез, клиническое значение в патологии костной ткани. Остеопороз и остеопатии. 2018;21(2):30-5. doi:10.14341/osteo9962.
47. Liu J, Huang F, He HW. Melatonin effects on hard tissues: bone and tooth. Int J Mol Sci. 2013;14(5):10063-74. doi:10.3390/ijms140510063.
48. Costa JL, Naot D, Lin JM, et al. Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro. Int J Pept. 2011;2011:605193. doi:10.1155/2011/605193.
49. Tosun A, Dogru MT, Aydin G, et al. Does autonomic dysfunction exist in postmenopausal osteoporosis? Am J Phys Med Rehabil. 2011;90(12):1012-9. doi:10.1097/PHM.0b013e31822dea1a.